

## STN Columbus

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRSEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	32	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	33	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS EXPRESS	JUNE 27 08		CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 16:42:46 ON 30 JUN 2008

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 30 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUN 2008 HIGHEST RN 1031692-95-1  
DICTIONARY FILE UPDATES: 29 JUN 2008 HIGHEST RN 1031692-95-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stncen/stndoc/properties.html>

=> e myriocin/cn

E1	1	MYRININ/CN
E2	1	MYRIOCARFIN/CN
E3	1 -->	MYRIOCIN/CN
E4	1	MYRIOCIN, ANHYDRO-/CN
E5	1	MYRIOGINIC ACID/CN
E6	1	MYRIOGININ/CN
E7	1	MYRIONEURINOL/CN
E8	1	MYRIONINE/CN
E9	1	MYRIONINE HYDRIODIDE/CN
E10	1	MYRIONINE HYDROCHLORIDE/CN
E11	1	MYRIOPHYLLOSIDE/CN
E12	1	MYRIOPHYLLOSIDE A/CN

=> s e3


L1 1 MYRIOCIN/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 35891-70-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 6-Eicosenoic acid, 2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-,  
(2S,3R,4R,6E)- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 6-Eicosenoic acid, 2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-,  
[2S-(2R\*,3S\*,4S\*,6E)]-  
OTHER NAMES:  
CN (+)-Myriocin  
CN (2S,3R,4R)-(E)-2-Amino-3,4-dihydroxy-2-hydroxymethyl-14-oxoeicos-6-enoic  
acid  
CN ISP-I  
CN **Myriocin**  
CN Thermozy mocidin  
FS STEREOSEARCH

DR 36564-60-0, 37836-36-5  
 MF C21 H39 N O6  
 LC STN Files: AGRICOLA, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS,  
 CASREACT, CHEMCATS, CSChem, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDb,  
 IMSDRUGNEWS, IMSRESEARCH, MEDLINE, NAPRALERT, PHAR, PROMT, PROUSDDR,  
 RTECS\*, TOXCENTER, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

126 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 127 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file drugu  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
8.07	8.28

FULL ESTIMATED COST

FILE 'DRUGU' ENTERED AT 16:44:06 ON 30 JUN 2008  
 COPYRIGHT (C) 2008 THOMSON REUTERS

FILE LAST UPDATED: 30 JUN 2008 <20080630/UP>  
 >>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<  
 >>> THESAURUS AVAILABLE IN /CT <<<

>>> PLEASE NOTE THAT THE COPYRIGHT NOTIFICATION HAS CHANGED <<<

=> s l1  
 L2 3 L1

=> d 1-3

L2 ANSWER 1 OF 3 DRUGU COPYRIGHT 2008 THOMSON REUTERS on STN

Full Text

AN 1993-19972 DRUGU C

TI A Formal Synthesis of a Novel Immunosuppressant ISP-1: Stereocontrolled  
 Pd(0) Catalyzed cis-Hydroxyamination of Carbohydrate Derived Vinyl  
 Epoxide.

AU Rao A V R; Gurjar M K; Devi T R; Kumar K R

LO Hyderabad, India

SO Tetrahedron Lett. (34, No. 10, 1653-56, 1993) 1 Fig. 14 Ref.

CODEN: TELEYA ISSN: 0040-4039

AV Indian Institute of Chemical Technology, Hyderabad 500 007, India.

LA English

DT Journal

FA AB; LA; CT; MPC

FS Literature

L2 ANSWER 2 OF 3 DRUGU COPYRIGHT 2008 THOMSON REUTERS on STN

AN 26347 DRUGU

FS Registry

DDRN MYRIOCIN

DDN MYRIOCIN

RN 35891-70-4

CT ANTIBIOTICS; IMMUNOSUPPRESSIVES

SS KETOACID; AMINOACID; HYDROXYACID; AMINOALCOHOL; POLYALCOHOL; OLEFIN  
 L2 ANSWER 3 OF 3 DRUGU COPYRIGHT 2008 THOMSON REUTERS on STN  
 AN 23353 DRUGU  
 FS Registry  
 DDRN THERMOZYM  
 DDN THERMOZYMOCIDIN  
 RN 35891-70-4  
 CT ANTIBIOTICS  
 SS KETOACID; AMINOACID; HYDROXYACID; AMINOALCOHOL; POLYALCOHOL OLEFIN  
 MPC 11% \*G; 114 \*G; 115 \*G; 118 \*G; 12% \*G; 124 \*G; 126 \*G; 127 \*G; 13% \*G;  
 130 \*G; 131 \*G; 133 \*G; 14- \*G; 153 \*G; 182 \*G; 190 \*G; 231 \*G; 232 \*G;  
 237 \*G

=> file medline  
 COST IN U.S. DOLLARS SINCE FILE TOTAL  
 ENTRY SESSION  
 FULL ESTIMATED COST 3.81 12.09

FILE 'MEDLINE' ENTERED AT 16:44:36 ON 30 JUN 2008

FILE LAST UPDATED: 28 Jun 2008 (20080628/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's  
 revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate  
 substance identification.

See HELP RANGE before carrying out any RANGE search.

=> s l1  
 L3 79 L1  
 => s myriocin  
 L4 102 MYRIOCIN  
 => s l3 or l4  
 L5 132 L3 OR L4  
 => s (serine palmitoyltransferase inhibit? or spt?)  
 105330 SERINE  
 2264 PALMITOYLTRANSFERASE  
 1430174 INHIBIT?  
 12 SERINE PALMITOYLTRANSFERASE INHIBIT?  
 (SERINE(W)PALMITOYLTRANSFERASE(W)INHIBIT?)  
 2970 SPT?  
 2979 (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)  
 L6  
 => s atherosclerosis  
 L7 56663 ATHEROSCLEROSIS  
 => s l5 and l7  
 L8 6 L5 AND L7  
 => s l6 and l7  
 L9 5 L6 AND L7  
 => d l8 l-6

L8 ANSWER 1 OF 6 MEDLINE on STN  
Full Text  
 AN 2008078932 MEDLINE  
 DN PubMed ID: 17963772  
 TI Ceramide: a common pathway for **atherosclerosis?**.  
 AU Bismuth Jean; Lin Peter; Yao Qizhi; Chen Changyi  
 CS Molecular Surgeon Research Center, Division of Vascular Surgery and  
 Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor  
 College of Medicine, Houston, TX, United States.  
 NC AT003094 (United States NCCAM)  
 DE15543 (United States NIDCR)

EB-002436 (United States NIBIB)  
 HL076345 (United States NHLBI)  
 HL083471 (United States NHLBI)  
 HL65916 (United States NHLBI)  
 HL72716 (United States NHLBI)

SO Atherosclerosis, (2008 Feb) Vol. 196, No. 2, pp. 497-504. Electronic  
 Publication: 2007-10-25. Ref: 92  
 Journal code: 0242543. E-ISSN: 1879-1484.

CY Ireland  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, N.I.H., EXTRAMURAL)  
 General Review; (REVIEW)

LA English  
 FS Priority Journals  
 EM 200803  
 ED Entered STN: 2 Feb 2008  
 Last Updated on STN: 25 Mar 2008  
 Entered Medline: 24 Mar 2008

L8 ANSWER 2 OF 6 MEDLINE on STN  
Full Text  
 AN 2008045038 MEDLINE  
 DN PubMed ID: 17978313  
 TI **Myricetin** slows the progression of established atherosclerotic lesions in  
 apolipoprotein E gene knockout mice.  
 AU Glaros Elias N; Kim Woojin S; Quinn Carmel M; Jessup Wendy; Rye  
 Kerry-Anne; Garner Brett  
 CS Prince of Wales Medical Research Institute, Randwick, NSW 2031, Australia.  
 SO Journal of lipid research, (2008 Feb) Vol. 49, No. 2, pp. 324-31.  
 Electronic Publication: 2007-10-31.  
 Journal code: 0376606. ISSN: 0022-2275.

CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English  
 FS Priority Journals  
 EM 200804  
 ED Entered STN: 18 Jan 2008  
 Last Updated on STN: 23 Apr 2008  
 Entered Medline: 22 Apr 2008

L8 ANSWER 3 OF 6 MEDLINE on STN  
Full Text  
 AN 2007183937 MEDLINE  
 DN PubMed ID: 17239624  
 TI Inhibition of **atherosclerosis** by the serine palmitoyl transferase  
 inhibitor **myricetin** is associated with reduced plasma glycosphingolipid  
 concentration.  
 AU Glaros Elias N; Kim Woojin S; Wu Benjamin J; Suarna Cacang; Quinn Carmel  
 M; Rye Kerry-Anne; Stocker Roland; Jessup Wendy; Garner Brett  
 CS Prince of Wales Medical Research Institute, Randwick, NSW 2031, Australia.  
 SO Biochemical pharmacology, (2007 May 1) Vol. 73, No. 9, pp. 1340-6.  
 Electronic Publication: 2006-12-27.  
 Journal code: 0101032. ISSN: 0006-2952.

CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200705  
 ED Entered STN: 28 Mar 2007  
 Last Updated on STN: 18 May 2007  
 Entered Medline: 17 May 2007

L8 ANSWER 4 OF 6 MEDLINE on STN  
Full Text  
 AN 2006633731 MEDLINE  
 DN PubMed ID: 16458317  
 TI Modulation of lipoprotein metabolism by inhibition of sphingomyelin  
 synthesis in ApoE knockout mice.  
 AU Park Tae-Sik; Panek Robert L; Rekhter Mark D; Mueller Sandra Bak; Rosebury  
 Wendy S; Robertson Andrew; Hanselman Jeffrey C; Kindt Erick; Homan  
 Reynold; Karathanasis Sotirios K

CS Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA.. [tp2156@columbia.edu](mailto:tp2156@columbia.edu)  
 SO Atherosclerosis, (2006 Dec) Vol. 189, No. 2, pp. 264-72. Electronic Publication: 2006-02-02.  
 Journal code: 0242543. ISSN: 0021-9150.  
 CY Ireland  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200701  
 ED Entered STN: 31 Oct 2006  
 Last Updated on STN: 31 Jan 2007  
 Entered Medline: 30 Jan 2007

L8 ANSWER 5 OF 6 MEDLINE on STN

Full Text

AN 2005132765 MEDLINE  
 DN PubMed ID: 15590644  
 TI Effect of **myriocin** on plasma sphingolipid metabolism and **atherosclerosis** in apoE-deficient mice.  
 AU Hojjati Mohammad Reza; Li Zhiqiang; Zhou Hongwen; Tang Songsan; Huan Chongmin; Ooi Evelyn; Lu Shendi; Jiang Xian-Cheng  
 CS Department of Anatomy and Cell Biology, State University of New York Downstate Medical Center, 450 Clarkson Ave., Brooklyn, New York 11203, USA.  
 NC HL-64735 (United States NHLBI)  
 HL-69817 (United States NHLBI)  
 SO The Journal of biological chemistry, (2005 Mar 18) Vol. 280, No. 11, pp. 10284-9. Electronic Publication: 2004-12-06.  
 Journal code: 2985121R. ISSN: 0021-9258.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
 LA English  
 FS Priority Journals  
 EM 200504  
 ED Entered STN: 15 Mar 2005  
 Last Updated on STN: 26 Apr 2005  
 Entered Medline: 25 Apr 2005

L8 ANSWER 6 OF 6 MEDLINE on STN

Full Text

AN 2004595840 MEDLINE  
 DN PubMed ID: 15569847  
 TI Sphingolipids and **atherosclerosis**: a mechanistic connection? A therapeutic opportunity?.  
 AU Tabas Ira  
 NC R01 HL56984 (United States NHLBI)  
 SO Circulation, (2004 Nov 30) Vol. 110, No. 22, pp. 3400-1.  
 Journal code: 0147763. E-ISSN: 1524-4539.  
 CY United States  
 DT Commentary  
 (COMPARATIVE STUDY)  
 Editorial  
 (RESEARCH SUPPORT, N.I.H., EXTRAMURAL)  
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200506  
 ED Entered STN: 1 Dec 2004  
 Last Updated on STN: 14 Jun 2005  
 Entered Medline: 13 Jun 2005

-> d his

(FILE 'HOME' ENTERED AT 16:42:46 ON 30 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 30 JUN 2008

E MYRIOCIN/CN

L1 1 S E3

L2 FILE 'DRUGU' ENTERED AT 16:44:06 ON 30 JUN 2008  
3 S L1

L3 FILE 'MEDLINE' ENTERED AT 16:44:36 ON 30 JUN 2008  
L4 79 S L1  
L5 102 S MYRIOCIN  
L6 132 S L3 OR L4  
L7 2979 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)  
L8 56663 S ATHEROSCLEROSIS  
L9 6 S L5 AND L7  
5 S L6 AND L7

=> d 19 1-5

L9 ANSWER 1 OF 5 MEDLINE on STN  
Full Text  
AN 2007476556 MEDLINE  
DN PubMed ID: 17602566  
TI Inhibition of reactive nitrogen species in vitro and ex vivo by trypsin inhibitor from sweet potato 'Tainong 57' storage roots.  
AU Huang Guan-Jhong; Sheu Ming-Jyh; Chen Hsien-Jung; Chang Yuan-Shiun; Lin Yaw-Huei  
CS Institute of Chinese Pharmaceutical Sciences and Department of Physiology, School of Medicine, China Medical University, Taichung 404, Taiwan..  
gjhuan@gmail.com.edu.tw  
SO Journal of agricultural and food chemistry, (2007 Jul 25) Vol. 55, No. 15, pp. 6000-6. Electronic Publication: 2007-06-28.  
Journal code: 0374755. ISSN: 0021-8561.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
LA English  
FS Priority Journals  
EM 200710  
ED Entered STN: 16 Aug 2007  
Last Updated on STN: 10 Oct 2007  
Entered Medline: 9 Oct 2007

L9 ANSWER 2 OF 5 MEDLINE on STN  
Full Text  
AN 2007183937 MEDLINE  
DN PubMed ID: 17239824  
TI Inhibition of **atherosclerosis** by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration.  
AU Glaros Elias N; Kim Woojin S; Wu Benjamin J; Suarna Cacang; Quinn Carmel M; Rye Kerry-Anne; Stocker Roland; Jessup Wendy; Garner Brett  
CS Prince of Wales Medical Research Institute, Randwick, NSW 2031, Australia.  
SO Biochemical pharmacology, (2007 May 1) Vol. 73, No. 9, pp. 1340-6.  
Electronic Publication: 2006-12-27.  
Journal code: 0101032. ISSN: 0006-2952.  
CY England: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200705  
ED Entered STN: 28 Mar 2007  
Last Updated on STN: 18 May 2007  
Entered Medline: 17 May 2007

L9 ANSWER 3 OF 5 MEDLINE on STN  
Full Text  
AN 2005578244 MEDLINE  
DN PubMed ID: 16216550  
TI Serine palmitoyl-CoA transferase (**SPT**) deficiency and sphingolipid levels in mice.  
AU Hojjati Mohammad Reza; Li Zhiqiang; Jiang Xian-Cheng  
CS Department of Anatomy and Cell Biology, SUNY Downstate Medical Center, 450 Clarkson Ave. Box 5, Brooklyn, NY 11203, USA.  
NC HL-64735 (United States NHLBI)  
HL-69817 (United States NHLBI)  
SO Biochimica et biophysica acta, (2005 Oct 15) Vol. 1737, No. 1, pp. 44-51.

Electronic Publication: 2005-08-24.  
 Journal code: 0217513. ISSN: 0006-3002.  
 CY Netherlands  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, N.I.H., EXTRAMURAL)  
 LA English  
 FS Priority Journals  
 EM 200512  
 ED Entered STN: 1 Nov 2005  
 Last Updated on STN: 22 Dec 2005  
 Entered Medline: 20 Dec 2005

L9 ANSWER 4 OF 5 MEDLINE on STN  
Full Text  
 AN 2005132765 MEDLINE  
 DN PubMed ID: 15590644  
 TI Effect of myriocin on plasma sphingolipid metabolism and **atherosclerosis**  
 in apoE-deficient mice.  
 AU Hojjati Mohammad Reza; Li Zhiqiang; Zhou Hongwen; Tang Songsshan; Huan  
 Chongmin; Ooi Evelyn; Lu Shendi; Jiang Xian-Cheng  
 CS Department of Anatomy and Cell Biology, State University of New York  
 Downstate Medical Center, 450 Clarkson Ave., Brooklyn, New York 11203,  
 USA.  
 NC HL-64735 (United States NHLBI)  
 HL-69817 (United States NHLBI)  
 SO The Journal of biological chemistry, (2005 Mar 18) Vol. 280, No. 11, pp.  
 10284-9. Electronic Publication: 2004-12-06.  
 Journal code: 2985121R. ISSN: 0021-9258.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
 LA English  
 FS Priority Journals  
 EM 200504  
 ED Entered STN: 15 Mar 2005  
 Last Updated on STN: 26 Apr 2005  
 Entered Medline: 25 Apr 2005

L9 ANSWER 5 OF 5 MEDLINE on STN  
Full Text  
 AN 2004595840 MEDLINE  
 DN PubMed ID: 15569847  
 TI Sphingolipids and **atherosclerosis**: a mechanistic connection? A  
 therapeutic opportunity?.  
 AU Tabas Ira  
 NC R01 HL56984 (United States NHLBI)  
 SO Circulation, (2004 Nov 30) Vol. 110, No. 22, pp. 3400-1.  
 Journal code: 0147763. E-ISSN: 1524-4539.  
 CY United States  
 DT Commentary  
 (COMPARATIVE STUDY)  
 Editorial  
 (RESEARCH SUPPORT, N.I.H., EXTRAMURAL)  
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 200506  
 ED Entered STN: 1 Dec 2004  
 Last Updated on STN: 14 Jun 2005  
 Entered Medline: 13 Jun 2005

=> file ca		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.84	15.93

FILE 'CA' ENTERED AT 16:47:26 ON 30 JUN 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)



Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jun 2008 VOL 149 ISS 1  
FILE LAST UPDATED: 26 Jun 2008 (20080626/ED)

CA now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 16:42:46 ON 30 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 30 JUN 2008

E MYRIOCIN/CN

L1 1 S E3

FILE 'DRUGU' ENTERED AT 16:44:06 ON 30 JUN 2008

L2 3 S L1

FILE 'MEDLINE' ENTERED AT 16:44:36 ON 30 JUN 2008

L3 79 S L1

L4 102 S MYRIOCIN

L5 132 S L3 OR L4

L6 2979 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)

L7 56663 S ATHEROSCLEROSIS

L8 6 S L5 AND L7

L9 5 S L6 AND L7

FILE 'CA' ENTERED AT 16:47:26 ON 30 JUN 2008

=> s l1

L10 126 L1

=> s myriocin/ab,bi

149 MYRIOCIN/AB

183 MYRIOCIN/BI

L11 183 MYRIOCIN/AB,BI

=> s l10 or l11

L12 208 L10 OR L11

=> s (serine palmitoyltransferase inhibit? or spt?)/ab,bi

85207 SERINE/AB

1726 PALMITOYLTRANSFERASE/AB

1685580 INHIBIT?/AB

12 SERINE PALMITOYLTRANSFERASE INHIBIT?/AB

((SERINE(W)PALMITOYLTRANSFERASE(W)INHIBIT?)/AB)

118540 SERINE/BI

2218 PALMITOYLTRANSFERASE/BI

1989932 INHIBIT?/BI

40 SERINE PALMITOYLTRANSFERASE INHIBIT?/BI

((SERINE(W)PALMITOYLTRANSFERASE(W)INHIBIT?)/BI)

2239 SPT?/AB

2657 SPT?/BI

L13 2680 (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)/AB,BI

=> s atherosclerosis/ab,bi

35883 ATHEROSCLEROSIS/AB  
58627 ATHEROSCLEROSIS/BI  
L14 58627 ATHEROSCLEROSIS/AB,BI

=> s l12 and l14  
L15 9 L12 AND L14

=> s l13 and l14  
L16 14 L13 AND L14

=> d l15 1-9

L15 ANSWER 1 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:557962 CA

TI SPTLC1 Binds ABCA1 To Negatively Regulate Trafficking and Cholesterol Efflux Activity of the Transporter

AU Tamehiro, Norimasa; Zhou, Suiping; Okuhira, Keiichiro; Benita, Yair; Brown, Cari E.; Zhuang, Debbie Z.; Latz, Eicke; Hornemann, Thorsten; von Eckardstein, Arnold; Xavier, Ramnik J.; Freeman, Mason W.; Fitzgerald, Michael L.

CS Lipid Metabolism Unit and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA, 02114, USA

SO Biochemistry (2008), 47(23), 6138-6147

CODEN: BICHAU; ISSN: 0006-2960

PB American Chemical Society

DT Journal

LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:235953 CA

TI **Myricocin** slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice

AU Glaros, Elias N.; Kim, Woojin S.; Quinn, Carmel M.; Jessup, Wendy; Rye, Kerry-Anne; Garner, Brett

CS Prince of Wales Medical Research Institute, Randwick NSW, 2031, Australia

SO Journal of Lipid Research (2008), 49(2), 324-331

CODEN: JLPRAW; ISSN: 0022-2275

PB American Society for Biochemistry and Molecular Biology, Inc.

DT Journal

LA English

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:492927 CA

TI Inhibition of **atherosclerosis** by the serine palmitoyl transferase inhibitor **myricocin** is associated with reduced plasma glycosphingolipid concentration

AU Glaros, Elias N.; Kim, Woojin S.; Wu, Benjamin J.; Suarna, Cacang; Quinn, Carmel M.; Rye, Kerry-Anne; Stocker, Roland; Jessup, Wendy; Garner, Brett

CS Prince of Wales Medical Research Institute, Randwick, 2031, Australia

SO Biochemical Pharmacology (2007), 73(9), 1340-1346

CODEN: BCPCA6; ISSN: 0006-2952

PB Elsevier B.V.

DT Journal

LA English

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:19933 CA

TI Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice

AU Park, Tae-Sik; Panek, Robert L.; Rekhter, Mark D.; Mueller, Sandra Bak; Rosebury, Wendy S.; Robertson, Andrew; Hanselman, Jeffrey C.; Kindt, Erick; Homan, Reynold; Karathanasis, Sotirios K.

CS Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI, 48105, USA  
 SO Atherosclerosis (Amsterdam, Netherlands) (2006), 189(2), 264-272  
 CODEN: ATHSBL; ISSN: 0021-9150  
 PE Elsevier B.V.  
 DT Journal  
 LA English  
 RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 144:390641 CA  
 TI Preparation of **myriocin** analogs for use in pharmaceutical compositions for treating insulin resistance and cardiomyopathy  
 IN Nestor, John  
 PA Therapei Pharmaceuticals, Inc., USA  
 SO U.S. Pat. Appl. Publ., 23 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060079542	A1	20060413	US 2005-248491	20051012
	US 7189748	B2	20070313		
	AU 2005295080	A1	20060420	AU 2005-295080	20051012
	CA 2583947	A1	20060420	CA 2005-2583947	20051012
	WO 2006042278	A1	20060420	WO 2005-US36702	20051012
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1799217	A1	20070627	EP 2005-809923		20051012
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101060845	A	20071024	CN 2005-80039238		20051012
JP 2008515987	T	20080515	JP 2007-536845		20051012
US 20070135450	A1	20070614	US 2006-618120		20061229
IN 2007DN02662	A	20070803	IN 2007-DN2662		20070410
MX 200704262	A	20080304	MX 2007-4262		20070411
KR 2007085250	A	20070827	KR 2007-708297		20070412
PRAI US 2004-617911P	P	20041012			
US 2005-664835P	P	20050323			
US 2005-664919P	P	20050323			
US 2005-693463P	P	20050623			
US 2005-248491	A1	20051012			
WO 2005-US36702	W	20051012			
OS CASREACT 144:390641; MARPAT 144:390641					
RE.CNT 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT					

L15 ANSWER 6 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 143:339656 CA  
 TI Use of a serine palmitoyltransferase (spt) inhibitor to treat **atherosclerosis** and dyslipidemia  
 IN Homan, Reynolds; Karathanasis, Sotirios Konstantinou; Panek, Robert Lee; Park, Tae-Sik; Rekhter, Mark David  
 PA Warner-Lambert Company LLC, USA  
 SO PCT Int. Appl., 53 pp.  
 CODEN: PIXXD2  
 DT Patent

LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092325	A1	20051006	WO 2005-IB733	20050321
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2560920	A1	20051006	CA 2005-2560920	20050321
	EP 1732538	A1	20061220	EP 2005-708781	20050321
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	BR 2005007998	A	20070731	BR 2005-7998	20050321
	JP 2007530528	T	20071101	JP 2007-504503	20050321
	MX 2006PA11060	A	20061116	MX 2006-PA11060	20060926
	US 20080027088	A1	20080131	US 2007-594348	20070815
PRAI	US 2004-557021P	P	20040326		
	WO 2005-IB733	W	20050321		
RE.CNT 7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L15 ANSWER 7 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 142:385619 CA  
TI Effect of **Myriocin** on Plasma Sphingolipid Metabolism and **Atherosclerosis** in apoE-deficient Mice  
AU Hojjati, Mohammad Reza; Li, Zhiqiang; Zhou, Hongwen; Tang, Songshan; Huan, Chongmin; Ooi, Evelyn; Lu, Shendi; Jiang, Xian-Cheng  
CS Department of Anatomy and Cell Biology, State University of New York Downstate Medical Center, Brooklyn, NY, 11203, USA  
SO Journal of Biological Chemistry (2005), 280(11), 10284-10289  
CODEN: JBCHA3; ISSN: 0021-9258  
PB American Society for Biochemistry and Molecular Biology  
DT Journal  
LA English  
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 142:111534 CA  
TI Inhibition of Sphingomyelin Synthesis Reduces Atherogenesis in Apolipoprotein E-Knockout Mice  
AU Park, Tae-Sik; Panek, Robert L.; Mueller, Sandra Bak; Hanselman, Jeffrey C.; Rosebury, Wendy S.; Robertson, Andrew W.; Kindt, Erick K.; Homan, Reynold; Karathanasis, Sotirios K.; Reikhter, Mark D.  
CS Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI, USA  
SO Circulation (2004), 110(22), 3465-3471  
CODEN: CIRCAZ; ISSN: 0009-7322  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 9 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 135:341174 CA  
TI Detection and treatment of **atherosclerosis** based on plasma sphingomyelin concentration  
IN Tall, Alan R.; Jiang, Xian-Cheng  
PA Trustees of Columbia University in the City of New York, USA  
SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001080903	A1	20011101	WO 2001-US12706	20010419
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2000-551947	A	20000419		
OS MARPAT 135:341174				

=> d his

(FILE 'HOME' ENTERED AT 16:42:46 ON 30 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 30 JUN 2008  
E MYRIOCIN/CN

L1 1 S E3

FILE 'DRUGU' ENTERED AT 16:44:06 ON 30 JUN 2008

L2 3 S L1

FILE 'MEDLINE' ENTERED AT 16:44:36 ON 30 JUN 2008

L3 79 S L1

L4 102 S MYRIOCIN

L5 132 S L3 OR L4

L6 2979 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)

L7 56663 S ATHEROSCLEROSIS

L8 6 S L5 AND L7

L9 5 S L6 AND L7

FILE 'CA' ENTERED AT 16:47:26 ON 30 JUN 2008

L10 126 S L1

L11 183 S MYRIOCIN/AB,BI

L12 208 S L10 OR L11

L13 2680 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)/AB,BI

L14 58627 S ATHEROSCLEROSIS/AB,BI

L15 9 S L12 AND L14

L16 14 S L13 AND L14

=> d l16 1-14

L16 ANSWER 1 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:557962 CA

TI SPTLC1 Binds ABCA1 To Negatively Regulate Trafficking and Cholesterol Efflux Activity of the Transporter

AU Tamehiro, Norimasa; Zhou, Suiping; Okuhira, Keiichi; Benita, Yair; Brown, Cari E.; Zhuang, Debbie Z.; Latz, Eicke; Hornemann, Thorsten; von Eckardstein, Arnold; Xavier, Ramnik J.; Freeman, Mason W.; Fitzgerald, Michael L.

CS Lipid Metabolism Unit and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA, 02114, USA

SO Biochemistry (2008), 47(23), 6138-6147

CODEN: BICHAW; ISSN: 0006-2960

PB American Chemical Society

DT Journal

LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:441026 CA  
 TI Preparation of cyclic and aliphatic compounds as serine  
 palmitoyltransferase modulators for treating metabolic syndrome and  
 inflammation  
 IN Nestor, John  
 PA Forbes Medi-Tech (Research), Inc., USA  
 SO PCT Int. Appl., 67pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008046071	A2	20080417	WO 2007-US813303	20071012
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20080139455	A1	20080612	US 2007-871720	20071012
PRAI US 2006-829277P	P	20061012		
OS MARPAT 148:441026				

L16 ANSWER 3 OF 14 CA COPYRIGHT 2008 ACS on STN

[Full Text](#)

AN 148:331424 CA  
 TI Preparation of benzene derivatives as serine palmitoyl transferase  
 inhibitors  
 IN Nestor, John  
 PA Forbes Medi-Tech (Research), Inc., USA  
 SO PCT Int. Appl., 64pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008031032	A2	20080313	WO 2007-US77884	20070907
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20080096799	A1	20080424	US 2007-851935	20070907
PRAI US 2006-824897P	P	20060907		
OS MARPAT 148:331424				

L16 ANSWER 4 OF 14 CA COPYRIGHT 2008 ACS on STN

[Full Text](#)

AN 147:539679 CA  
 TI Alleles and polymorphisms associated with type 2 diabetes mellitus and  
 obesity and their diagnostic use  
 IN Salonen, Jukka T.; Hypponen, Jelenia; Kaikkonen, Jari; Pirskanen, Mia;  
 Uimari, Pekka; Aalto, Juha-Matti  
 PA Oy Jurilab Ltd., Finland  
 SO PCT Int. Appl., 456pp.  
 CODEN: PIXXD2  
 DT Patent

LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007128884	A1	20071115	WO 2007-FI50266	20070509
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AN, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20070292412	A1	20071220	US 2007-798002	20070509
PRAI	US 2006-798706P	P	20060509		
	US 2006-798774P	P	20060509		
	US 2006-805522P	P	20060622		
	US 2006-819015P	P	20060707		
	US 2006-827306P	P	20060928		
	US 2006-863438P	P	20061030		
	US 2006-864681P	P	20061107		

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 147:79006 CA  
TI Inhibition of reactive nitrogen species in vitro and ex vivo by trypsin inhibitor from sweet potato 'Tainong 57' storage roots  
AU Huang, Guan-Jhong; Sheu, Ming-Jyh; Chen, Hsien-Jung; Chang, Yuan-Shiun; Lin, Yaw-Huei  
CS Institute of Chinese Pharmaceutical Sciences and Department of Physiology, School of Medicine, China Medical University, Taichung, 404, Taiwan  
SO Journal of Agricultural and Food Chemistry (2007), 55(15), 6000-6006  
CODEN: JAFCAU; ISSN: 0021-8561  
PB American Chemical Society  
DT Journal  
LA English  
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:492927 CA  
TI Inhibition of **atherosclerosis** by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration  
AU Glaros, Elias N.; Kim, Woojin S.; Wu, Benjamin J.; Suarna, Cacang; Quinn, Carmel M.; Rye, Kerry-Anne; Stocker, Roland; Jessup, Wendy; Garner, Brett  
CS Prince of Wales Medical Research Institute, Randwick, 2031, Australia  
SO Biochemical Pharmacology (2007), 73(9), 1340-1346  
CODEN: BCPA6; ISSN: 0006-2952  
PB Elsevier B.V.  
DT Journal  
LA English  
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:19933 CA  
TI Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice  
AU Park, Tae-Sik; Panek, Robert L.; Rekhter, Mark D.; Mueller, Sandra Bak; Rosebury, Wendy S.; Robertson, Andrew; Hanselman, Jeffrey C.; Kindt, Erick; Homan, Reynold; Karathanasis, Sotirios K.  
CS Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI, 48105, USA

SO Atherosclerosis (Amsterdam, Netherlands) (2006), 189(2), 264-272  
 CODEN: ATHSBL; ISSN: 0021-9150  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 144:49621 CA  
 TI Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice  
 AU Hojjati, Mohammad Reza; Li, Zhiqiang; Jiang, Xian-Cheng  
 CS Department of Anatomy and Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, 11203, USA  
 SO Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids (2005), 1737(1), 44-51  
 CODEN: BBMLFG; ISSN: 1388-1981  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 143:339656 CA  
 TI Use of a serine palmitoyltransferase (spt) inhibitor to treat atherosclerosis and dyslipidemia  
 IN Homan, Reynold; Karathanasis, Sotirios Konstantinou; Panek, Robert Lee; Park, Tae-Sik; Rekhter, Mark David  
 PA Warner-Lambert Company LLC, USA  
 SO PCT Int. Appl., 53 pp.  
 CODEN: PIIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005092325	A1	20051006	WO 2005-IB733	20050321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LI, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2560920	A1	20051006	CA 2005-2560920	20050321
EP 1732538	A1	20061220	EP 2005-708781	20050321
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
BR 2005007998	A	20070731	BR 2005-7998	20050321
JP 2007530528	T	20071101	JP 2007-504503	20050321
MX 2006PA11060	A	20061116	MX 2006-PA11060	20060926
US 20080027088	A1	20080131	US 2007-594348	20070815
PRAI US 2004-557021P	P	20040326		
WO 2005-IB733	W	20050321		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 143:272498 CA  
 TI Gene expression profiles in the diagnosis and treatment of Alzheimer's disease  
 IN Landfield, Philip W.; Porter, Nada M.; Chen, Kuey Chu; Geddes, James; Blalock, Eric



PA University of Kentucky Research Foundation, USA  
 SO PCT Int. Appl., 114 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005076939	A2	20050825	WO 2005-US3668	20050209
	WO 2005076939	A3	20060706		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 20070082350	A1	20070412	US 2006-501226	20060809
PRAI	US 2004-542281P	P	20040209		
	WO 2005-US3668	A	20050209		

L16 ANSWER 11 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 142:385619 CA  
 TI Effect of Myricetin on Plasma Sphingolipid Metabolism and **Atherosclerosis** in apoE-deficient Mice  
 AU Hojjati, Mohammad Reza; Li, Zhiqiang; Zhou, Hongwen; Tang, Songshan; Huan, Chongmin; Ooi, Evelyn; Lu, Shendi; Jiang, Xian-Cheng  
 CS Department of Anatomy and Cell Biology, State University of New York Downstate Medical Center, Brooklyn, NY, 11203, USA  
 SO Journal of Biological Chemistry (2005), 280(11), 10284-10289  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PB American Society for Biochemistry and Molecular Biology  
 DT Journal  
 LA English  
 RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 12 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 140:40262 CA  
 TI Genes expressed in atherosclerotic tissue and their use in diagnosis and pharmacogenetics  
 IN Nevins, Joseph; West, Mike; Goldschmidt, Pascal  
 PA Duke University, USA  
 SO PCT Int. Appl., 408 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003091391	A2	20031106	WO 2002-XB38221	20021112
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GR, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	WO 2003091391	A2	20031106	WO 2002-US38221	20021112
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-374547P P 20020423  
 US 2002-420784P P 20021024  
 US 2002-421043P P 20021025  
 US 2002-424680P P 20021108  
 WO 2002-US38221 A 20021112

L16 ANSWER 13 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 137:243916 CA

TI Method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications

IN Carton, Jill M.; D'Andrea, Michael R.; Uhlinger, David J.

PA Ortho-McNeil Pharmaceutical, Inc., USA

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074924	A2	20020926	WO 2002-US8383	20020319
WO 2002074924	A3	20030605		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002254286	A1	20021003	AU 2002-254286	20020319
US 20020197654	A1	20021226	US 2002-100861	20020319
EP 1379679	A2	20040114	EP 2002-723511	20020319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CN 1610751	A	20050427	CN 2002-810014	20020319
JP 2005523416	T	20050804	JP 2002-574317	20020319
MX 2003PA08487	A	20050307	MX 2003-PA8487	20030919
PRAI US 2001-277252P	P	20010320		
WO 2002-US8383	W	20020319		

L16 ANSWER 14 OF 14 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 130:2669 CA

TI Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin

AU Memon, Riaz A.; Holleran, Walter M.; Moser, Arthur H.; Seki, Taisuke; Uchida, Yoshikazu; Fuller, John; Shigenaga, Judy K.; Grunfeld, Carl; Feingold, Kenneth R.

CS Department of Medicine, University of California, San Francisco, San Francisco, CA, USA

SO Arteriosclerosis, Thrombosis, and Vascular Biology (1998), 18(8), 1257-1265

CODEN: ATVBFA; ISSN: 1079-5642

FB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d kwic ab 14

L16 ANSWER 14 OF 14 CA COPYRIGHT 2008 ACS on STN

AB . . . infections. The authors studied the effects of endotoxin

[lipopolysaccharide (LPS)] and cytokines on hepatic sphingolipid synthesis, activity of serine palmitoyltransferase (**SPT**), the first and rate-limiting enzyme in sphingolipid synthesis, and lipoprotein sphingolipid content in Syrian hamsters. Administration of LPS induced a 2-fold increase in hepatic **SPT** activity. The increase in activity first occurred at 16 h, peaked at 24 h, and was sustained for at least 48 h. Low doses of LPS produced maximal increases in **SPT** activity, with half-maximal effect seen at  $\approx 0.3 \mu\text{g}$  LPS/100 g body wt. LPS increased hepatic **SPT** mRNA levels 2-fold, suggesting that the increase in **SPT** activity was due to an increase in **SPT** mRNA. LPS treatment also produced 75% and 2.5-fold increases in hepatic sphingomyelin and ceramide synthesis, resp. Many of the metabolic effects of LPS are mediated by cytokines. Interleukin 1 (IL-1), but not tumor necrosis factor, increased both **SPT** activity and mRNA levels in the liver of intact animals, whereas both IL-1 and tumor necrosis factor increased **SPT** mRNA levels in HepG2 cells. IL-1 produced a 3-fold increase in **SPT** mRNA in HepG2 cells, and the half-maximal dose was 2 ng/mL. IL-1 also increased the secretion of sphingolipids into the . . .

IT Acute-phase response  
**Atherosclerosis**  
 Liver  
 (endotoxin and cytokines increase of hepatic sphingolipid formation and generation of lipoproteins enriched in ceramides and sphingomyelin in relation to atherogenesis)

AB Alterations in triglyceride and cholesterol metab. often accompany inflammatory diseases and infections. The authors studied the effects of endotoxin [lipopolysaccharide (LPS)] and cytokines on hepatic sphingolipid synthesis, activity of serine palmitoyltransferase (**SPT**), the first and rate-limiting enzyme in sphingolipid synthesis, and lipoprotein sphingolipid content in Syrian hamsters. Administration of LPS induced a 2-fold increase in hepatic **SPT** activity. The increase in activity first occurred at 16 h, peaked at 24 h, and was sustained for at least 48 h. Low doses of LPS produced maximal increases in **SPT** activity, with half-maximal effect seen at  $\approx 0.3 \mu\text{g}$  LPS/100 g body wt. LPS increased hepatic **SPT** mRNA levels 2-fold, suggesting that the increase in **SPT** activity was due to an increase in **SPT** mRNA. LPS treatment also produced 75% and 2.5-fold increases in hepatic sphingomyelin and ceramide synthesis, resp. Many of the metabolic effects of LPS are mediated by cytokines. Interleukin 1 (IL-1), but not tumor necrosis factor, increased both **SPT** activity and mRNA levels in the liver of intact animals, whereas both IL-1 and tumor necrosis factor increased **SPT** mRNA levels in HepG2 cells. IL-1 produced a 3-fold increase in **SPT** mRNA in HepG2 cells, and the half-maximal dose was 2 ng/mL. IL-1 also increased the secretion of sphingolipids into the medium. Anal. of serum lipoprotein fractions demonstrated that very low d. lipoprotein, intermediate d. lipoprotein, and low d. lipoprotein isolated from animals treated with LPS contained higher amts. of ceramide, glucosylceramide, and sphingomyelin. Thus, LPS and cytokines stimulate hepatic sphingolipid synthesis, which results in an altered structure of circulating lipoproteins and may promote atherogenesis.

-> d kwic ab 13

L16 ANSWER 13 OF 14 CA COPYRIGHT 2008 ACS on STN

AB The present invention is directed to a method for comparatively measuring the level of normal and hyperproliferative serine palmitoyltransferase (**SPT**) expression in a mammalian cell and uses thereof. The distribution of the **SPT1** and **SPT2** subunits may serve as a potential marker of cell activity, where high levels of the enzyme may reflect increased metabolic activity or cell proliferation. The assocn. of increased **SPT** expression in pathophysiol. states, such as cancer, inflammation, and vascular injury, make it a provocative therapeutic target. Diagnostic and drug screening applications of the **SPT** assay of the invention are described.

IT Medical goods  
 (catheters, balloon, coated by drug contg. **serine palmitoyltransferase inhibitor**; method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications)

IT Asthma  
**Atherosclerosis**  
 Carcinoid

Carcinoma  
 Inflammation  
 Leukemia  
 Lymphoma  
 Melanoma  
 Multiple myeloma  
 Neoplasm  
 Neuroglia, neoplasm  
 Rheumatoid arthritis  
 Sarcoma

(diagnosis and treatment of; method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications)

IT Drugs

(**serine palmitoyltransferase inhibitor**

-contg.; method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications)

IT Cytotoxic agents

(**serine palmitoyltransferase inhibitor**;

method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications)

IT Medical goods

(stents, coated by drug contg. **serine**

**palmitoyltransferase inhibitor**; method for measuring serine palmitoyltransferase expression in normal and hyperproliferative mammalian tissues and diagnostic and therapeutic applications)

AB The present invention is directed to a method for comparatively measuring the level of normal and hyperproliferative serine palmitoyltransferase (**SPT**) expression in a mammalian cell and uses thereof. The distribution of the **SPT1** and **SPT2** subunits may serve as a potential marker of cell activity, where high levels of the enzyme may reflect increased metabolic activity or cell proliferation. The assocn. of increased **SPT** expression in pathophysiol. states, such as cancer, inflammation, and vascular injury, make it a provocative therapeutic target. Diagnostic and drug screening applications of the **SPT** assay of the invention are described.

=> file uspatall

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

57.46

73.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.50

-1.50

FILE 'USPATFULL' ENTERED AT 16:51:14 ON 30 JUN 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 16:51:14 ON 30 JUN 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:51:14 ON 30 JUN 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d 11

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> s 11

L17 13 L1

=> s myriocin

L18 72 MYRIOCIN

=> s myriocin/clm

L19 9 MYRIOCIN/CLM

=> s (serine palmitoyltransferase inhibit? or spt?)

L20 7642 (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)

```

=> s (serine palmitoyltransferase inhibit? or spt?)/clm
L21      981 (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)/CLM

=> s atherosclerosis
L22      42005 ATHEROSCLEROSIS

=> s atherosclerosis/clm
L23      7443 ATHEROSCLEROSIS/CLM

=> s l17 or l18
L24      74 L17 OR L18

=> s l22 and l24
L25      18 L22 AND L24

=> s l17 and l19
L26      6 L17 AND L19

=> s l23 and l26
L27      1 L23 AND L26

=> d

L27 ANSWER 1 OF 1 USPATFULL on STN
Full Text
AN      2008:30792 USPATFULL
TI      Imidazole-Based Hmg-CoA Reductase Inhibitors
IN      Homan, Reynold, Ann Arbor, MI, UNITED STATES
        Karathanasis, Sotirios K., Carmel, IN, UNITED STATES
        Paneek, Robert L., Ann Arbor, MI, UNITED STATES
        Park, Tae-Sik, Ann Arbor, MI, UNITED STATES
        Rekhter, Mark D., Carmel, IN, UNITED STATES
PA      Warner-Lambert Company, LLC (U.S. corporation)
PI      US 20080027088 A1 20080131
AI      US 2005-594348 A1 20050321 (10)
        WO 2005-IB733 20050321
        20070815 PCI 371 date
PRAI    US 2004-557021P 20040326 (60)
DT      Utility
FS      APPLICATION
LN,CNT  1702
INCL     INCLM: 514/275.000
        INCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;
        514/789.000
NCL      NCLM: 514/275.000
        NCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;
        514/789.000
IC      IPCI A61K0031-185 [I,A]; A61K0031-185 [I,C*]; A61K0031-351 [I,A];
        A61K0031-405 [I,A]; A61K0031-403 [I,C*]; A61K0031-455 [I,A];
        A61K0031-47 [I,A]; A61K0031-505 [I,A]; A61P0003-04 [I,A];
        A61P0003-10 [I,A]; A61P0003-00 [I,C*]
        IPCR A61K0031-185 [I,C]; A61K0031-201 [I,A]; A61K0031-21 [I,C*];
        A61K0031-22 [I,A]; A61K0031-345 [I,C*]; A61K0031-345 [I,A];
        A61K0031-351 [I,C]; A61K0031-351 [I,A]; A61K0031-403 [I,C];
        A61K0031-405 [I,A]; A61K0031-455 [I,C]; A61K0031-455 [I,A];
        A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0031-505 [I,C];
        A61K0031-505 [I,A]; A61P0003-00 [I,C]; A61P0003-04 [I,A];
        A61P0003-10 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l20 and l22
L28      373 L20 AND L22

=> s l21 and l23
L29      6 L21 AND L23

=> d l-6

L29 ANSWER 1 OF 6 USPATFULL on STN
Full Text

```

AN 2008:160048 USPATFULL  
 TI COMPOUNDS AND METHODS OF TREATING METABOLIC SYNDROME AND INFLAMMATION  
 IN Nestor, John J., Encinitas, CA, UNITED STATES  
 PA Forbes Medi-Tech (Research), Inc., Seattle, WA, UNITED STATES (U.S. corporation)  
 PI US 20080139455 A1 20080612  
 AI US 2007-871720 A1 20071012 (11)  
 PRAI US 2006-829277P 20061012 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2844  
 INCL INCLM: 514 4  
 INCLS: 514/364.000; 514/394.000; 514/256.000; 514/357.000; 514/399.000; 544/335.000; 546/335.000; 548/131.000; 548/309.700; 548/339.100; 562/567.000; 560/037.000; 514/538.000; 514/561.000; 514/012.000; 435/011.000  
 NCL NCLM: 514 4  
 NCLS: 514/364.000; 514/394.000; 514/256.000; 514/357.000; 514/399.000; 544/335.000; 546/335.000; 548/131.000; 548/309.700; 548/339.100; 562/567.000; 560/037.000; 514/538.000; 514/561.000; 514/012.000; 435/011.000  
 IC IPCI A61K0038-28 [I,A]; A61P0003-00 [I,A]; A61K0031-4245 [I,A]; A61K0031-4184 [I,A]; A61K0031-505 [I,A]; A61K0031-44 [I,A]; A61K0031-4164 [I,A]; A61K0031-19 [I,A]; A61K0031-185 [I,C\*]; A61P0003-04 [I,A]; A61P0011-00 [I,A]; A61P0003-10 [I,A]; A61P0029-00 [I,A]; A61P0009-00 [I,A]; A61K0038-22 [I,A]; A61K0031-215 [I,A]; A61K0031-21 [I,C\*]; C07D0239-26 [I,A]; C07D0239-00 [I,C\*]; C07D0213-55 [I,A]; C07D0213-00 [I,C\*]; C07D0271-06 [I,A]; C07D0271-00 [I,C\*]; C07D0235-16 [I,A]; C07D0235-00 [I,C\*]; C07D0233-64 [I,A]; C07D0233-00 [I,C\*]

L29 ANSWER 2 OF 6 USPATFULL on STN

Full Text

AN 2008:111249 USPATFULL  
 TI COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION  
 IN Nestor, John, Encinitas, CA, UNITED STATES  
 PA FORBES MEDI-TECH (RESEARCH), INC., Seattle, WA, UNITED STATES, 98101 (U.S. corporation)  
 PI US 20080096799 A1 20080424  
 AI US 2007-851935 A1 20070907 (11)  
 PRAI US 2006-824897P 20060907 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 2893  
 INCL INCLM: 514/003.000  
 INCLS: 544/335.000; 514/256.000  
 NCL NCLM: 514/003.000  
 NCLS: 514/256.000; 544/335.000  
 IC IPCI A61K0038-28 [I,A]; A61P0003-10 [I,A]; A61P0003-00 [I,C\*]; C07D0239-02 [I,A]; C07D0239-00 [I,C\*]; A61K0031-4965 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 3 OF 6 USPATFULL on STN

Full Text

AN 2008:30792 USPATFULL  
 TI Imidazole-Based Hmg-CoA Reductase Inhibitors  
 IN Homan, Reynold, Ann Arbor, MI, UNITED STATES  
 Karathanasis, Sotirios K., Carmel, IN, UNITED STATES  
 Panek, Robert L., Ann Arbor, MI, UNITED STATES  
 Park, Tae-Sik, Ann Arbor, MI, UNITED STATES  
 Rekhter, Mark D., Carmel, IN, UNITED STATES  
 PA Warner-Lambert Company, LLC (U.S. corporation)  
 PI US 20080027088 A1 20080131  
 AI US 2005-594348 A1 20050321 (10)  
 WO 2005-IB733 20050321  
 PRAI US 2004-557021P 20040326 PCT 371 date  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1702  
 INCL INCLM: 514/275.000

INCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;  
 514/789.000  
 NCL NCLM: 514/275.000  
 NCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;  
 514/789.000  
 IC IPCI A61K0031-201 [I,A]; A61K0031-185 [I,C\*]; A61K0031-351 [I,A];  
 A61K0031-405 [I,A]; A61K0031-403 [I,C\*]; A61K0031-455 [I,A];  
 A61K0031-47 [I,A]; A61K0031-505 [I,A]; A61P0003-04 [I,A];  
 A61P0003-10 [I,A]; A61P0003-00 [I,C\*]  
 IPCR A61K0031-185 [I,C]; A61K0031-201 [I,A]; A61K0031-21 [I,C\*];  
 A61K0031-22 [I,A]; A61K0031-345 [I,C\*]; A61K0031-345 [I,A];  
 A61K0031-351 [I,C]; A61K0031-351 [I,A]; A61K0031-403 [I,C];  
 A61K0031-405 [I,A]; A61K0031-455 [I,C]; A61K0031-455 [I,A];  
 A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0031-505 [I,C];  
 A61K0031-505 [I,A]; A61P0003-00 [I,C]; A61P0003-04 [I,A];  
 A61P0003-10 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 4 OF 6 USPAIFULL on STN

Full Text

AN 2007:155230 USPAIFULL  
 TI Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy  
 IN Nestor, John, 725 Lynwood Drive, Encinitas, CA, UNITED STATES 92024  
 PA FORBES MEDI-TECH (RESEARCH), INC., Seattle, WA, UNITED STATES, 98101  
 (U.S. corporation)  
 PI US 20070135450 A1 20070614  
 AI US 2006-618120 A1 20061229 (11)  
 RLI Continuation of Ser. No. US 2005-248491, filed on 12 Oct 2005, GRANTED,  
 Pat. No. US 7189748  
 PRAI US 2004-617911P 20041012 (60)  
 US 2005-664835P 20050323 (60)  
 US 2005-664919P 20050323 (60)  
 US 2005-693463P 20050623 (60)  
 DT Utility  
 FS APPLICATION  
 LN,CNT 1513  
 INCL INCLM: 514/256.000  
 INCLS: 514/357.000; 514/374.000; 514/534.000; 514/400.000; 514/365.000;  
 514/367.000; 514/378.000; 514/375.000; 546/336.000; 544/242.000;  
 548/152.000; 548/205.000; 548/217.000; 548/235.000; 548/335.500;  
 562/452.000  
 NCL NCLM: 514/256.000  
 NCLS: 514/357.000; 514/365.000; 514/367.000; 514/374.000; 514/375.000;  
 514/378.000; 514/400.000; 514/534.000; 544/242.000; 546/336.000;  
 548/152.000; 548/205.000; 548/217.000; 548/235.000; 548/335.500;  
 562/452.000  
 IC IPCI A61K0031-505 [I,A]; A61K0031-44 [I,A]; A61K0031-428 [I,A];  
 A61K0031-426 [I,A]; A61K0031-421 [I,A]; A61K0031-4172 [I,A];  
 A61K0031-4164 [I,C\*]; A61K0031-195 [I,A]; A61K0031-185 [I,C\*]  
 IPCR A61K0031-505 [I,C]; A61K0031-505 [I,A]; A61K0031-185 [I,C];  
 A61K0031-195 [I,A]; A61K0031-4164 [I,C]; A61K0031-4172 [I,A];  
 A61K0031-421 [I,C]; A61K0031-421 [I,A]; A61K0031-426 [I,C];  
 A61K0031-426 [I,A]; A61K0031-428 [I,C]; A61K0031-428 [I,A];  
 A61K0031-44 [I,C]; A61K0031-44 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 5 OF 6 USPAIFULL on STN

Full Text

AN 2006:93411 USPAIFULL  
 TI Compounds and methods for treating insulin resistance and cardiomyopathy  
 IN Nestor, John, Encinitas, CA, UNITED STATES  
 PA Therapei Pharmaceuticals, Inc., San Diego, CA, UNITED STATES (U.S.  
 corporation)  
 PI US 20060079542 A1 20060413  
 US 7189748 B2 20070313  
 AI US 2005-248491 A1 20051012 (11)  
 PRAI US 2004-617911P 20041012 (60)  
 US 2005-664835P 20050323 (60)  
 US 2005-664919P 20050323 (60)  
 US 2005-693463P 20050623 (60)  
 DT Utility  
 FS APPLICATION

LN.CNT 1522  
 INCL INCLM: 514/269.000  
 INCLS: 514/365.000; 514/357.000; 514/374.000; 514/367.000; 514/378.000;  
 514/397.000; 514/400.000; 514/400.000; 514/375.000; 514/567.000; 544/309.000;  
 546/335.000; 548/204.000; 548/236.000; 548/248.000; 548/335.500;  
 562/452.000  
 NCL NCLM: 514/364.000; 514/269.000  
 NCLS: 514/400.000; 548/136.000; 548/340.100; 514/357.000; 514/365.000;  
 514/367.000; 514/374.000; 514/375.000; 514/378.000; 514/397.000;  
 514/567.000; 544/309.000; 546/335.000; 548/204.000; 548/236.000;  
 548/248.000; 548/335.500; 562/452.000  
 IC IPCI A61K0031-513 [I,A]; A61K0031-44 [I,A]; A61K0031-426 [I,A];  
 A61K0031-421 [I,A]; A61K0031-42 [I,A]  
 IPCI-2 A61K0031-41 [I,A]; A61K0031-4164 [I,A]; C07D0233-56 [I,A];  
 C07D0233-00 [I,C\*]; C07D0271-10 [I,A]; C07D0271-00 [I,C\*]  
 IPCR A61K0031-41 [I,C]; A61K0031-41 [I,A]; A61K0031-4164 [I,C];  
 A61K0031-4164 [I,A]; C07D0233-00 [I,C]; C07D0233-56 [I,A];  
 C07D0271-00 [I,C]; C07D0271-10 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L29 ANSWER 6 OF 6 USPAIFULL on STN

Full Text

AN 2002:343928 USPAIFULL  
 TI Method for measuring serine palmitoyltransferase in mammalian tissue and  
 use thereof  
 IN Carton, Jill M., Malvern, PA, UNITED STATES  
 D'Andrea, Michael R., Cherry Hill, NJ, UNITED STATES  
 Uhlinger, David J., Flemington, NJ, UNITED STATES  
 PI US 20020197654 A1 20021226  
 AI US 2002-100861 A1 20020319 (10)  
 PRAI US 2001-277252P 20010320 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1687  
 INCL INCLM: 435/007.210  
 INCLS: 424/009.600  
 NCL NCLM: 435/007.210  
 NCLS: 424/009.600  
 IC [7]  
 ICM G01N033-567  
 IPCI G01N033-567 [ICM,7]  
 IPCR C07K0016-40 [I,C\*]; C07K0016-40 [I,A]; C12N0009-10 [I,C\*];  
 C12N0009-10 [I,A]; C12Q0001-48 [I,C\*]; C12Q0001-48 [I,A];  
 G01N033-50 [I,C\*]; G01N033-50 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:42:46 ON 30 JUN 2008)

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 30 JUN 2008

E MYRIOCIN/CN

L1 1 S E3

FILE 'DRUGU' ENTERED AT 16:44:06 ON 30 JUN 2008

L2 3 S L1

FILE 'MEDLINE' ENTERED AT 16:44:36 ON 30 JUN 2008

L3 79 S L1

L4 102 S MYRIOCIN

L5 132 S L3 OR L4

L6 2979 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)

L7 56663 S ATHEROSCLEROSIS

L8 6 S L5 AND L7

L9 5 S L6 AND L7

FILE 'CA' ENTERED AT 16:47:26 ON 30 JUN 2008

L10 126 S L1

L11 183 S MYRIOCIN/AB,BI

L12 208 S L10 OR L11

L13 2680 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)/AB,BI



L14 58627 S ATHEROSCLEROSIS/AB,BI  
 L15 9 S L12 AND L14  
 L16 14 S L13 AND L14

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 16:51:14 ON 30 JUN 2008

L17 13 S L1  
 L18 72 S MYRIOCIN  
 L19 9 S MYRIOCIN/CLM  
 L20 7642 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)  
 L21 981 S (SERINE PALMITOYLTRANSFERASE INHIBIT? OR SPT?)/CLM  
 L22 42005 S ATHEROSCLEROSIS  
 L23 7443 S ATHEROSCLEROSIS/CLM  
 L24 74 S L17 OR L18  
 L25 18 S L22 AND L24  
 L26 6 S L17 AND L19  
 L27 1 S L23 AND L26  
 L28 373 S L20 AND L22  
 L29 6 S L21 AND L23

=> d 126 106

6 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE  
 The answer numbers requested are not in the answer set.  
 ENTER ANSWER NUMBER OR RANGE (1):end

=> d 126 1-6

L26 ANSWER 1 OF 6 USPATFULL on STN

Full Text

AN 2008:93774 USPATFULL  
 TI CEREBROSPINAL FLUID SHUNT HAVING LONG TERM ANTI-OCCLUSION AGENT DELIVERY  
 IN Trescony, Paul V., Champlin, MN, UNITED STATES  
 Koulick, Edouard, Golden Valley, MN, UNITED STATES  
 PA Medtronic, Inc., Minneapolis, MN, UNITED STATES (U.S. corporation)  
 PI US 20080082036 A1 20080403  
 AI US 2006-380157 A1 20060425 (11)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 745  
 INCL INCLM: 604 8  
 INCLS: 604/034.000  
 NCL NCLM: 604/008.000  
 NCLS: 604/034.000  
 IC IPCI A61F0002-20 [I,A]; A61M0001-00 [I,A]  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 2 OF 6 USPATFULL on STN

Full Text

AN 2008:30792 USPATFULL  
 TI Imidazole-Based Hmg-CoA Reductase Inhibitors  
 IN Homan, Reynold, Ann Arbor, MI, UNITED STATES  
 Karathanasis, Sotirios K., Carmel, IN, UNITED STATES  
 Panek, Robert L., Ann Arbor, MI, UNITED STATES  
 Park, Tae-Sik, Ann Arbor, MI, UNITED STATES  
 Rekhter, Mark D., Carmel, IN, UNITED STATES  
 PA Warner-Lambert Company, LLC (U.S. corporation)  
 PI US 20080027088 A1 20080131  
 AI US 2005-594348 A1 20050321 (10)  
 WO 2005-IB733 20050321  
 20070815 PCT 371 date  
 PRAI US 2004-4557021P 20040326 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1702  
 INCL INCLM: 514/275.000  
 INCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;  
 514/789.000  
 NCL NCLM: 514/275.000  
 NCLS: 514/311.000; 514/356.000; 514/415.000; 514/460.000; 514/560.000;  
 514/789.000  
 IC IPCI A61K0031-201 [I,A]; A61K0031-185 [I,C\*]; A61K0031-351 [I,A];  
 A61K0031-405 [I,A]; A61K0031-403 [I,C\*]; A61K0031-455 [I,A];  
 A61K0031-47 [I,A]; A61K0031-505 [I,A]; A61P0003-04 [I,A];

IPCRA61P0003-10 [I,A]; A61P0003-00 [I,C\*]  
A61K0031-185 [I,C]; A61K0031-201 [I,A]; A61K0031-21 [I,C\*];  
A61K0031-22 [I,A]; A61K0031-345 [I,C\*]; A61K0031-345 [I,A];  
A61K0031-351 [I,C]; A61K0031-351 [I,A]; A61K0031-403 [I,C];  
A61K0031-405 [I,A]; A61K0031-455 [I,C]; A61K0031-455 [I,A];  
A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0031-505 [I,C];  
A61K0031-505 [I,A]; A61P0003-00 [I,C]; A61P0003-04 [I,A];  
A61P0003-10 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 3 OF 6 USPATFULL on STN

Full Text

AN 2007:224176 USPATFULL  
TI ORAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS  
IN Eddington, Natalie D., School of Pharmacy, UMB, Dept. of Pharma. Sci.,  
20 Penn Street, HSF II 543, Baltimore, MD, UNITED STATES 21201  
Fasano, Alessio, 3128 River Valley Chase, West Friendship, MD, UNITED  
STATES 21794  
Song, Keon-Hyoung, 3113 West Springs Drive, Apt. F, Ellicott City, MD,  
UNITED STATES 21043  
PA UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD, UNITED STATES, 21201  
(U.S. corporation)  
PI US 20070196272 A1 20070823  
AI US 2007-673192 A1 20070209 (11)  
PRAI US 2006-771453P 20060209 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1321  
INCL INCLM: 424/001.110  
INCLS: 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/008.000;  
514/012.000; 514/003.000; 514/011.000; 514/171.000; 514/056.000;  
514/044.000; 424/094.630; 514/018.000  
NCL NCLM: 424/001.110  
NCLS: 424/094.630; 514/003.000; 514/008.000; 514/011.000; 514/012.000;  
514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000;  
514/044.000; 514/056.000; 514/171.000  
IC IPCI A61K0051-00 [I,A]; A61K0038-28 [I,A]; A61K0038-14 [I,A];  
A61K0038-22 [I,A]; A61K0031-727 [I,A]; A61K0031-726 [I,C\*];  
A61K0038-48 [I,A]; A61K0038-43 [I,C]; A61K0031-56 [I,A];  
A61M0036-14 [I,A]; A61M0036-00 [I,C\*]  
IPCR A61K0051-00 [I,C]; A61K0051-00 [I,A]; A61K0031-56 [I,C];  
A61K0031-56 [I,A]; A61K0031-726 [I,C]; A61K0031-727 [I,A];  
A61K0038-14 [I,C]; A61K0038-14 [I,A]; A61K0038-22 [I,C];  
A61K0038-22 [I,A]; A61K0038-28 [I,C]; A61K0038-28 [I,A];  
A61K0038-43 [I,C]; A61K0038-48 [I,A]; A61M0036-00 [I,C];  
A61M0036-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 4 OF 6 USPATFULL on STN

Full Text

AN 2006:314702 USPATFULL  
TI Antibiotic kit and composition and uses thereof  
IN Friedman, Doron, Karmel Yosef, ISRAEL  
Besonov, Alex, Rehovot, ISRAEL  
Tamarkin, Dov, Maccabim, ISRAEL  
Eini, Meir, Ness Ziona, ISRAEL  
PA Foamix Ltd., Rehovot, ISRAEL (non-U.S. corporation)  
PI US 20060269485 A1 20061130  
AI US 2006-448490 A1 20060607 (11)  
RLI Continuation-in-part of Ser. No. US 2004-911367, filed on 4 Aug 2004,  
PENDING Continuation-in-part of Ser. No. US 2005-532618, filed on 22 Dec  
2005, PENDING A 371 of International Ser. No. WO 2003-IB5527, filed on  
24 Oct 2003  
PRAI US 2003-492385P 20030804 (60)  
US 2002-429546P 20021129 (60)  
US 2005-688244P 20050607 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2938  
INCL INCLM: 424/045.000  
NCL NCLM: 424/045.000  
IC IPCI A61L0009-04 [I,A]

IPCR A61L0009-04 [I,C]; A61L0009-04 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 5 OF 6 USPATFULL on STN

Full Text

AN 2005:209536 USPATFULL  
TI Ceramide de novo synthesis-based therapeutic and prophylactic methods,  
and related articles of manufacture  
IN Worgall, Tilla S., New York, NY, UNITED STATES  
Deckelbaum, Richard J., Hastings-on-Hudson, NY, UNITED STATES  
PI US 20050182020 A1 20050818  
AI US 2003-712684 A1 20031114 (10)  
DT Utility  
FS APPLICATION  
LN.CNT 1544  
INCL INCLM: 514/054.000  
INCLS: 514/560.000; 514/475.000; 514/651.000; 514/733.000  
NCL NCLM: 514/054.000  
NCLS: 514/475.000; 514/560.000; 514/651.000; 514/733.000  
IC [7]  
ICM A61K031-739  
ICS A61K031-336; A61K031-202; A61K031-138; A61K031-05  
IPCI A61K0031-739 [ICM,7]; A61K0031-336 [ICS,7]; A61K0031-202 [ICS,7];  
A61K0031-185 [ICS,7,C\*]; A61K0031-138 [ICS,7]; A61K0031-05  
[ICS,7]; A61K0031-045 [ICS,7,C\*]  
IPCR A61K0031-00 [I,C\*]; A61K0031-00 [I,A]; A61K0031-045 [I,C\*];  
A61K0031-05 [I,A]; A61K0031-138 [I,C\*]; A61K0031-138 [I,A];  
A61K0031-185 [I,C\*]; A61K0031-202 [I,A]; A61K0031-336 [I,C\*];  
A61K0031-336 [I,A]; A61K0031-739 [I,C\*]; A61K0031-739 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 6 OF 6 USPATFULL on STN

Full Text

AN 75:70458 USPATFULL  
TI Myriocin and process of preparation  
IN Kluepfel, Dieter, Montreal, Canada  
Kudelski, Alicia, Westmount, Canada  
Bagli, Jehan, Kirkland, Canada  
PA Ayerst McKenna and Harrison Ltd., Montreal, Canada (non-U.S.  
corporation)  
PI US 3928572 19751223  
AI US 1971-114445 19710211 (5)  
DT Utility  
FS Granted  
LN.CNT 310  
INCL INCLM: 424/122.000  
INCLS: 195/081.000  
NCL NCLM: 424/122.000  
NCLS: 435/128.000; 435/911.000  
IC [2]  
ICM H61K035-00  
IPCI H61K0035-00 [ICM,2]  
IPCR A61K0031-185 [I,C\*]; A61K0031-195 [I,A]  
EXF 424/122; 195/81

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> kwic 6

KWIC IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> d l26 kwic 6

L26 ANSWER 6 OF 6 USPATFULL on STN

CLM What is claimed is:  
1. **Myriocin**, a compound which a. is effective in inhibiting the growth  
of pathogenic fungi; b. is soluble in methanol, somewhat less. . .  
CLM What is claimed is:  
2. **Myriocin**, of claim 1 which is trans-2-amino-3,4-dihydroxy  
-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid having the structural

formula ##SPC2##

CLM    What is claimed is:  
3. A process for the production of **myriocin**, trans-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid which comprises culturing a suspension of spores of *Myriococcum albomyces* NRRL 3858 in an aqueous nutrient medium containing. . . and a temperature of about 40° to 55°C until substantial anti-fungal activity is imparted to the medium by production of **myriocin**, and recovering **myriocin** from the culture medium.

CLM    What is claimed is:  
. . . out by filtering the fermentation mixture, extracting the mycelial growth with a lower alkanol, evaporating said extract and purifying crude **myriocin** thus obtained by crystallization.

IT    35891-70-4P  
      (manuf. of, with *Myriococcum albomyces*)

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
28.71	102.10

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-1.50

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:57:22 ON 30 JUN 2008